tiprankstipranks
Trending News
More News >
Uscom Limited (AU:UCM)
ASX:UCM
Australian Market

Uscom Limited (UCM) AI Stock Analysis

Compare
0 Followers

Top Page

AU

Uscom Limited

(Sydney:UCM)

Rating:46Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Uscom Limited's overall stock score reflects its primary challenges in financial performance and valuation. While the company shows revenue growth, ongoing profitability issues, negative cash flow, and a concerning valuation significantly impact the score. The technical analysis remains neutral, providing no strong indication of momentum.

Uscom Limited (UCM) vs. iShares MSCI Australia ETF (EWA)

Uscom Limited Business Overview & Revenue Model

Company DescriptionUscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company also provides the SpiroSonic AIR, a digital multipath ultrasonic spirometer with a viral disinfection system for the elimination of COVID and tuberculosis; and respiratory devices. It serves hospitals and other medical care locations through a network of distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.
How the Company Makes MoneyUscom Limited generates revenue through the sale of its medical devices to hospitals, clinics, and healthcare providers globally. The company also earns income from service contracts, maintenance agreements, and software upgrades associated with its products. Key revenue streams include direct sales, distributor partnerships, and government contracts, which help expand its market reach. Additionally, Uscom may benefit from strategic collaborations with research institutions and healthcare organizations, further enhancing its product offerings and market penetration.

Uscom Limited Financial Statement Overview

Summary
Uscom Limited shows revenue growth but faces significant profitability challenges with consistently negative EBIT and net income. The balance sheet indicates manageable leverage but declining equity ratios, while cash flow issues persist with negative free cash flow.
Income Statement
45
Neutral
Uscom Limited shows a fluctuation in its revenue, with a notable increase in the recent year. However, the company has consistently reported negative EBIT and net income, indicating ongoing profitability challenges. While the gross profit has improved, the net profit margin remains negative, which is a significant concern.
Balance Sheet
55
Neutral
The balance sheet reflects a moderate debt-to-equity ratio, suggesting manageable leverage levels. However, the equity ratio has been declining, indicating potential risks in asset management. The return on equity has been negative, highlighting the company's struggle to generate profit from its equity base.
Cash Flow
50
Neutral
Cash flow analysis reveals persistent negative free cash flow, though operating cash flow has shown some improvement in recent periods. The free cash flow to net income ratio remains unfavorable, suggesting that the company is facing challenges in converting profits into cash.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
3.63M3.73M2.66M2.51M3.86M3.48M
Gross Profit
3.04M3.12M-1.03M-1.21M781.70K458.00K
EBIT
-2.70M-2.38M-2.92M-2.61M-1.43M-1.80M
EBITDA
-2.09M-1.51M-2.53M-1.84M-833.84K-672.88K
Net Income Common Stockholders
-2.36M-2.07M-2.59M-1.97M-924.24K-1.33M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.48M2.52M2.18M4.70M1.71M1.92M
Total Assets
5.50M5.13M5.18M7.99M5.33M5.92M
Total Debt
1.60M989.28K1.09M1.31M1.43M1.62M
Net Debt
115.47K-1.53M-787.15K-376.91K-265.40K-288.21K
Total Liabilities
2.38M2.07M2.14M2.06M2.26M2.50M
Stockholders Equity
3.12M3.06M3.04M5.94M3.08M3.42M
Cash FlowFree Cash Flow
-1.52M-1.22M-1.58M-1.08M21.63K-321.38K
Operating Cash Flow
-1.51M-1.16M-1.42M-967.51K54.98K-283.23K
Investing Cash Flow
-56.85K-57.55K-151.94K-115.31K-33.35K-38.16K
Financing Cash Flow
536.63K1.57M-952.96K4.05M-281.87K1.03M

Uscom Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.02
Price Trends
50DMA
0.02
Negative
100DMA
0.02
Negative
200DMA
0.02
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
50.05
Neutral
STOCH
80.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:UCM, the sentiment is Neutral. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.05 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:UCM.

Uscom Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
AUUCM
46
Neutral
AU$5.01M-117.20%2.91%13.51%
DE1I4
€4.50M-321.94%
AUADR
47
Neutral
AU$5.31M-375.15%-59.01%17.06%
AUCBL
41
Neutral
AU$10.31M-98.08%-7.44%30.34%
AUAT1
39
Underperform
AU$10.98M-61.15%35.63%18.55%
AUIRX
38
Underperform
AU$8.54M-191.40%19.74%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:UCM
Uscom Limited
0.02
0.00
0.00%
DE:1I4
HeraMED Ltd.
0.01
0.00
0.00%
AU:AT1
Atomo Diagnostics Ltd.
0.02
>-0.01
-33.33%
AU:ADR
Adherium Ltd.
0.01
-0.01
-50.00%
AU:IRX
InhaleRx Limited
0.04
0.01
33.33%
AU:CBL
Control Bionics Ltd.
0.04
-0.01
-20.00%

Uscom Limited Corporate Events

Uscom Limited Reports Increased Revenue Amid Global Challenges
Apr 29, 2025

Uscom Limited released its quarterly cash report for the period ending March 31, 2025, showing a 14% increase in customer receipts compared to the previous quarter, despite a challenging global trade environment. The company’s operational highlights include significant clinical achievements, strengthened partnerships with Foxconn and SinoPharm, and the establishment of a new subsidiary in China to support expansion. With new products and strategic partnerships, Uscom is well-positioned for growth in anticipation of a more stable global economic environment.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.